ÜRÜN, Y. Et Al. 2019. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.25, no.7 , 1658-1664.

ÜRÜN, Y., Yasar, H. A., TURNA, Z. H., Esin, E., Sedef, A. M., Alkan, A., ... Oksuzoglu, B.(2019). Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.25, no.7, 1658-1664.

ÜRÜN, YÜKSEL Et Al. "Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.25, no.7, 1658-1664, 2019

ÜRÜN, YÜKSEL Et Al. "Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.25, no.7, pp.1658-1664, 2019

ÜRÜN, Y. Et Al. (2019) . "Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.25, no.7, pp.1658-1664.

@article{article, author={YÜKSEL ÜRÜN Et Al. }, title={Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2019, pages={1658-1664} }